Novanta (NOVT) Could Be 31% Below Fair Value On Its Medical Growth Story

Simply Wall St.10-16

Recent price moves put Novanta (NOVT) back under the microscope for investors. The stock closed at US$134.80 on 16 October 2026, with returns mixed across recent time frames. Short term momentum for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675858568?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/8131000-choice2-card/1788974837715","is_english":true,"pubTime":"2026-10-16 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675858568","market":"hk","top_or_hot":-1,"title":"Novanta (NOVT) Could Be 31% Below Fair Value On Its Medical Growth Story","media":"Simply Wall St.","content":"<div>\n<p>Recent price moves put Novanta (NOVT) back under the microscope for investors. The stock closed at US$134.80 on 16 October 2026, with returns mixed across recent time frames. Short term momentum for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/tech/nasdaq-novt/novanta/news/novanta-novt-could-be-31-below-fair-value-on-its-medical-gro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novanta (NOVT) Could Be 31% Below Fair Value On Its Medical Growth Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovanta (NOVT) Could Be 31% Below Fair Value On Its Medical Growth Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-16 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/tech/nasdaq-novt/novanta/news/novanta-novt-could-be-31-below-fair-value-on-its-medical-gro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent price moves put Novanta (NOVT) back under the microscope for investors. The stock closed at US$134.80 on 16 October 2026, with returns mixed across recent time frames. Short term momentum for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/tech/nasdaq-novt/novanta/news/novanta-novt-could-be-31-below-fair-value-on-its-medical-gro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0012050646.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","start_time":0,"source_url":"https://simplywall.st/stocks/us/tech/nasdaq-novt/novanta/news/novanta-novt-could-be-31-below-fair-value-on-its-medical-gro","article_id":"2675858568","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/8131000-choice2-card/1788974837715"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/tech/nasdaq-novt/novanta/news/novanta-novt-could-be-31-below-fair-value-on-its-medical-gro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2675858568","pubTimestamp":1792117676,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent price moves put Novanta (NOVT) back under the microscope for investors. The stock closed at US$134.80 on 16 October 2026, with returns mixed across recent time frames.\nShort term momentum for Novanta has cooled, with the share price return down 3.76% over one day and 9.35% over 90 days. However, the year-to-date share price return of 21.29% and 1 year total shareholder return of 26.44% still point to stronger recent performance than the longer term 3 and 5 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4157":"电子设备和仪器","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","NOVT":"Novanta Inc.","RTOO":"Vistashares Robotics Supercycle Etf","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC"},"translate_title":"Novanta (NOVT) 的医疗增长故事可能比公允价值低 31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTOO":0.6,"NOVT":1.5},"content_text":"Recent price moves put Novanta (NOVT) back under the microscope for investors. The stock closed at US$134.80 on 16 October 2026, with returns mixed across recent time frames. Short term momentum for Novanta has cooled, with the share price return down 3.76% over one day and 9.35% over 90 days. However, the year-to-date share price return of 21.29% and 1 year total shareholder return of 26.44% still point to stronger recent performance than the longer term 3 and 5 year total shareholder returns. Scan beyond Novanta and line up its recent swings against a curated set of 91 robotics and automation stocks that share similar exposure to automation and precision technologies. After a sharp run this year followed by a cooler patch, the real question on Novanta now is whether the recent pullback leaves enough reward to justify the remaining risk as valuation comes under the spotlight. AdvertisementMost Popular Narrative: 31% Undervalued On the most followed view, Novanta’s fair value sits at $194.50, well above the recent $134.80 close. This puts execution risk and future growth firmly in focus for readers weighing the pullback.  Expansion of minimally invasive and robotic surgery, together with the Riverpoint Medical acquisition that roughly doubles recurring medical consumables revenue to about US$300 million and lifts medical exposure to around 60% of sales, increases Novanta's mix of repeat consumables that can support more resilient revenue and gross margin over time.  See why 6 investors see Novanta as 31% undervalued. Result: Fair Value of $194.50 (UNDERVALUED) Still, higher leverage after the US$1.45b Riverpoint Medical deal and pressure on Medical Solutions margins could quickly weaken confidence in the Novanta thesis. Find out about the key risks to this Novanta narrative. Another View: Rich Multiples Keep Novanta In Check The story around Novanta’s fair value looks very different once the focus shifts to simple earnings multiples. On a P/E of 82.5x versus 29.3x for the US Electronic industry and 52.5x for peers, the stock trades on a much richer tag that raises clear valuation risk. The fair ratio sits at 40.6x, roughly half the current level. This suggests there could be significant scope for that multiple to compress if expectations cool. For anyone weighing the recent pullback, the question is whether future growth can support this premium or if the market is already paying up. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:NOVT P/E Ratio as at Oct 2026Next Steps Mixed signals on Novanta’s valuation and risk can feel messy, so move quickly, test the numbers for yourself, and weigh the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Novanta? If Novanta has you thinking harder about risk and reward, do not stop here. Fresh ideas elsewhere could shift how you position your next move.  Target resilience first and filter for companies that prioritise balance sheet strength with the list of solid balance sheet and fundamentals (25 results). Spot potential value gaps early by scanning a curated set of 32 high quality undervalued stocks before attention moves elsewhere. Optimize for smoother rides in rough markets by focusing on 32 resilient stocks with low risk scores that still meet your quality bar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novanta might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675858568","isCrawlerRequest":true}